Effects on anemia of drug adjustment in patients with chronic hepatitis C during telaprevir-combined therapy

Effects on anemia of drug adjustment in patients with chronic hepatitis C during telaprevir-combined therapy

Aim. Anemia is the most common adverse event in patients with chronic hepatitis C virus (HCV) treated with telaprevir (TVR) combined triple therapy. We examined the effects of drug dose adjustment on anemia and a sustained viral response (sVR) during combination therapy.Material and methods. This st...

Full description

Bibliographic Details
Main Authors: Akihiro Tamori, Kiyohide Kioka, Hiroki Sakaguchi, Masaru Enomoto, Hoang Hai, Etsushi Kawamura, Atsushi Hagihara, Hideki Fujii, Sawako Uchida-Kobayashi, Shuji Iwai, Hiroyasu Morikawa, Yoshiki Murakami, Yasuko Kawasaki, Daisuke Tsuruta, Norifumi Kawada
Format: Article
Language:English
Published: Elsevier 2015-01-01
Series:Annals of Hepatology
Subjects:
Adverse effects
Peg-interferon a2b
Ribavirin
Randomized control study
Sustained viral response
Online Access:http://www.sciencedirect.com/science/article/pii/S1665268119307987

Internet

http://www.sciencedirect.com/science/article/pii/S1665268119307987

Similar Items